Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Stock Rated “Buy” by Wall Street Brokerages

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) has received a consensus rating of “Buy” from the seventeen ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and three have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $56.25.

A number of equities research analysts have commented on the company. JonesTrading started coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price target for the company. BTIG Research restated a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Lifesci Capital upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, October 15th. Guggenheim assumed coverage on shares of Sensei Biotherapeutics in a report on Wednesday, September 16th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, TD Cowen initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, September 9th. They issued a “buy” rating for the company.

Sensei Biotherapeutics Stock Down 1.5%

NASDAQ FTH opened at $16.83 on Tuesday. The business has a fifty day moving average price of $29.91. The stock has a market capitalization of $434.89 million, a price-to-earnings ratio of -0.12 and a beta of -0.29. Sensei Biotherapeutics has a 12-month low of $7.45 and a 12-month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, analysts forecast that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics in the first quarter worth $22,758,000. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics during the first quarter valued at $4,188,000. Alyeska Investment Group L.P. acquired a new position in shares of Sensei Biotherapeutics in the 2nd quarter valued at $3,610,000. Bank of America Corp DE increased its position in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares during the period. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.